Total Payments
$180,520
2024 Payments
$28,173
Companies
13
Transactions
79
Medicare Patients
725
Medicare Billing
$92,143
Payment Breakdown by Category
Consulting$103,040 (57.1%)
Travel$53,193 (29.5%)
Research$18,240 (10.1%)
Education$2,499 (1.4%)
Other$2,430 (1.3%)
Food & Beverage$1,118 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $103,040 | 24 | 57.1% |
| Travel and Lodging | $53,193 | 24 | 29.5% |
| Unspecified | $18,240 | 8 | 10.1% |
| Education | $2,499 | 3 | 1.4% |
| Honoraria | $2,430 | 1 | 1.3% |
| Food and Beverage | $1,118 | 19 | 0.6% |
Payments by Type
General
$162,281
71 transactions
Research
$18,240
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharma AG | $61,700 | 21 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $39,623 | 15 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $21,960 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $21,500 | 10 | $0 (2020) |
| The Medicines Company | $16,563 | 2 | $0 (2018) |
| Gilead Sciences Inc | $8,032 | 2 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $7,546 | 9 | $0 (2018) |
| CSL Behring | $2,563 | 4 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $654.32 | 2 | $0 (2019) |
| AstraZeneca AB | $201.09 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,173 | 12 | Novartis Pharma AG ($22,164) |
| 2023 | $43,411 | 16 | Novartis Pharma AG ($39,535) |
| 2022 | $17,842 | 3 | NOVARTIS PHARMACEUTICALS CORPORATION ($12,075) |
| 2020 | $3,238 | 2 | AstraZeneca Pharmaceuticals LP ($1,750) |
| 2019 | $19,548 | 14 | Boehringer Ingelheim International GmbH ($15,393) |
| 2018 | $31,829 | 14 | Boehringer Ingelheim International GmbH ($16,992) |
| 2017 | $36,479 | 18 | AstraZeneca Pharmaceuticals LP ($12,750) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | — | Cash or cash equivalent | $1,310.23 | Research |
| Study: CKJX839A1US02 • Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $37.48 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/11/2024 | Novartis Pharma AG | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $8,425.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | — | Cash or cash equivalent | $324.09 | Research |
| Study: CKJX839A1US02 • Category: Cardiology/Vascular Diseases | ||||||
| 05/29/2024 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $12,178.03 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/29/2024 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $324.81 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/29/2024 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $253.66 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/28/2024 | Novartis Pharma AG | LEQVIO (Drug) | Education | In-kind items and services | $829.49 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/28/2024 | Novartis Pharma AG | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $59.17 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/26/2024 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $56.64 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $174.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/28/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | — | Cash or cash equivalent | $2,409.44 | Research |
| Study: NCT03399370,NCT03400800 • Category: Cardiology/Vascular Diseases | ||||||
| 09/12/2023 | Novartis Pharma AG | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $9,475.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2023 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $4,394.15 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2023 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $1,355.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2023 | Novartis Pharma AG | LEQVIO (Drug) | Education | Cash or cash equivalent | $1,124.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2023 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $789.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/22/2023 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $56.16 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/08/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | — | Cash or cash equivalent | $356.50 | Research |
| Study: CKJX839A12306B • Category: Cardiology/Vascular Diseases | ||||||
| 06/06/2023 | Novartis Pharma AG | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $9,300.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/24/2023 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $10,799.15 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/24/2023 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $601.38 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/24/2023 | Novartis Pharma AG | LEQVIO (Drug) | Education | Cash or cash equivalent | $545.23 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/24/2023 | Novartis Pharma AG | LEQVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $519.05 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $12,075 | 1 |
| NCT03399370,NCT03400800 | Novartis Pharmaceuticals Corporation | $2,409 | 1 |
| CKJX839A1US02 | Novartis Pharmaceuticals Corporation | $1,634 | 2 |
| CKJX839A12201E1 | Novartis Pharmaceuticals Corporation | $1,110 | 1 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $654.32 | 2 |
| CKJX839A12306B | Novartis Pharmaceuticals Corporation | $356.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 170 | 179 | $78,230 | $22,963 |
| 2022 | 6 | 177 | 197 | $79,155 | $24,951 |
| 2021 | 5 | 215 | 240 | $35,164 | $26,839 |
| 2020 | 5 | 163 | 174 | $22,476 | $17,391 |
Total Patients
725
Total Services
790
Medicare Billing
$92,143
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 96 | 104 | $46,280 | $14,288 | 30.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $10,854 | $2,979 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 26 | $7,376 | $2,636 | 35.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $8,092 | $2,230 | 27.6% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 14 | 14 | $5,628 | $831.09 | 14.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 81 | 97 | $43,165 | $13,569 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $19,296 | $5,735 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $7,616 | $2,195 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 20 | $5,800 | $1,900 | 32.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 13 | 14 | $2,450 | $1,125 | 45.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 15 | 18 | $828.00 | $427.32 | 51.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 97 | $17,408 | $13,229 | 76.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 28 | 28 | $6,504 | $4,912 | 75.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $6,274 | $4,728 | 75.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 29 | $3,735 | $2,824 | 75.6% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 39 | 50 | $1,243 | $1,145 | 92.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 97 | 106 | $15,707 | $11,910 | 75.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 18 | 18 | $3,702 | $2,904 | 78.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 11 | 11 | $1,194 | $958.58 | 80.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 11 | $1,194 | $956.04 | 80.1% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 26 | 28 | $679.39 | $662.19 | 97.5% |
About Dr. R Wright, M.D
Dr. R Wright, M.D is a Cardiovascular Disease healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558333922.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. R Wright, M.D has received a total of $180,520 in payments from pharmaceutical and medical device companies, with $28,173 received in 2024. These payments were reported across 79 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($103,040).
As a Medicare-enrolled provider, Wright has provided services to 725 Medicare beneficiaries, totaling 790 services with total Medicare billing of $92,143. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Rochester, MN
- Active Since 02/01/2006
- Last Updated 08/21/2020
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1558333922
Products in Payments
- LEQVIO (Drug) $83,660
- JARDIANCE (Drug) $39,623
- EPANOVA (Drug) $21,701
- PRALUENT (Drug) $7,546
- PRALUENT ALIROCUMAB INJECTION (Biological) $562.86
- PRALUENT (Biological) $91.46
- Repatha (Biological) $20.89
- CAMZYOS (Drug) $16.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Rochester
Samuel Asirvatham, M.d, M.D
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Srijoy Mahapatra, M.d, M.D
Cardiovascular Disease — Payments: $1.2M
Cardiovascular Disease $1.2M
Amir Lerman, M.d, M.D
Cardiovascular Disease — Payments: $590,259
Cardiovascular Disease $590,259
Charanjit Rihal, M.d, M.D
Cardiovascular Disease — Payments: $484,688
Cardiovascular Disease $484,688
Martha Grogan, M.d, M.D
Cardiovascular Disease — Payments: $402,326
Cardiovascular Disease $402,326
David Hayes, M.d, M.D
Cardiovascular Disease — Payments: $278,959
Cardiovascular Disease $278,959